| 前收盘价格 | 35.59 |
| 收盘价格 | 35.92 |
| 成交量 | 986,912 |
| 平均成交量 (3个月) | 1,151,150 |
| 市值 | 2,157,629,952 |
| 价格/销量 (P/S) | 30.13 |
| 股市价格/股市净资产 (P/B) | 0.840 |
| 52周波幅 | |
| 利润日期 | 30 Jul 2026 |
| 营业毛利率 | 1,798.26% |
| 营业利益率 (TTM) | -1,221.97% |
| 稀释每股收益 (EPS TTM) | 11.54 |
| 季度收入增长率 (YOY) | 6.60% |
| 总债务/股东权益 (D/E MRQ) | 3.61% |
| 流动比率 (MRQ) | 18.50 |
| 营业现金流 (OCF TTM) | -401.46 M |
| 杠杆自由现金流 (LFCF TTM) | -237.66 M |
| 资产报酬率 (ROA TTM) | -22.88% |
| 股东权益报酬率 (ROE TTM) | 60.26% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Agios Pharmaceuticals, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.50 |
|
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 1.65% |
| 机构持股比例 | 101.39% |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| CAPELLO JEFFREY D | - | - | 0 | 0 |
| OWEN ADAMS CATHERINE | - | - | 0 | 0 |
| 累积净数量 | 0 | |||
| 累积净值 ($) | 0 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| CAPELLO JEFFREY D | 董事 | 13 Jun 2026 | 执行期权 | 1,976 | - | - |
| OWEN ADAMS CATHERINE | 董事 | 13 Jun 2026 | 执行期权 | 1,976 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合